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Summary : Whether or not there is an asso-   
ciation between HLA antigen(s) and/or
haplotypes aud relapse in patients success-
fully treated for pulmonary tuberculosis was
examined. Serological determination of HLA
-A, - B, -DR and -DQ antigens was carried
out in patients with quiescent pulmonary tu-
berculosis and bacteriologically relapsed pa-
tients, after treatment with short course che-
motherapy with Rifampicin, Isoniazid,
Pyrazinamide and Streptomycin or
Ethambutol in various combinations for 6-8
month Au increased antigen frequency of
HLA -Al (P = 0.03) and B17 was seen in pa-
tients with bacteriological relapse compared
with those with quiescent disease. The rela-
tive risks (RR) were Al = 2.8 and B17 = 3.2,
respectively, The haplotypes Al-B17 (RR =
3.3), B17-DR7 (RR = 3.0), Al-DR7 (p = 0.04;
RR = 9.3) were very common in patients
with bacteriological relapse. This increase of
HLA-Al, B17 antigens or the haplotypes Al-
B 17, B17-DR7 or Al-DR7 (P = 0.04) was seen
irrespective of the treatment regimen. The
present study suggests that HLA -Al (and -
B17) antigen(s), as such, and/or haplotypes Al- :
DR7 or non-HLA genes linked closer to HLA
-A, -B and -DR loci may be associated with
relapse of pulmonary tuberculosis, after che-
motherapy.
INTRODUCTION
Pulmonary tuberculosis is a granulomatous lung
disease caused by M. tuberculosis. Treatment with
short course chemotherapy with Rifampicin
containing drug regimens has proved to be highly
effective1,2. Inspite of successful treatment with
these drugs, a proportion of patients relapse, which
requires retreatment2,3. These relapses may be either
due to “endogenous reactivation”, where the
dormant forms of the organism (persisters) start
multiplying again, after completing the treatment,
due to the trigger provided either by the host factors
and/or environmental factors. The other reason
suggested for relapse is “exogenous reinfection”4,5.
It is well established that the immune status of
the host is regulated by HLA genes/gene products
which play a major role in cell-mediated and
humoral immune responses to any pathogen or
antigen6.
The present study was carried out to understand
the association, if any, between HLA genetic fac-
tors and relapse of pulmonary tuberculosis, after
successful treatment with short course chemo-
therapy.
MATERIAL AND METHODS
Study Subjects
For  the  s tudy ,  51  pa t ien t s  who  had  a
bacteriological relapse after 6-8 months’ treatment
with short course chemotherapy were selected. An
equal number of patients with quiescent disease,
matched for treatment regimen and duration of
follow up was also selected. The primary treatment
regimen consisted of Rifampicin, Isoniazid,
Pyrazinamide and Streptomycin (or Ethambutol)
for the initial phase and 2 or 3 drugs in the
continuation phase for 6 to 8 months. All the
patients had bacilli sensitive to Streptomycin,
Isoniazid and Rifampicin, initially. Of the 51
relapses, 39 had occurred in the first 12 months of
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follow up. Care was taken to select controls who
were not related to the patients with relapse.
Among the 51 relapse cases, 43 were males,
mean age was 33.0 with SE ± 1.8 years, and for the
8 females, mean age was 32.8 with SE ± 5.1 years.
Among the quiescent cases, 35 were males, mean
age was 32.1 with SE ± 1.5 years and for 16
females, mean age was 29.5 with SE ± 2.1 years.
Peripheral blood mononuclear cells
Twenty milliliters of peripheral blood in heparin
(20 units/ml) was drawn from each patient. The
blood specimens were subjected to ficoll-hypaque
density gradient centrifugation as described by
Boyum7. The mononuclear cells were separated and
washed in TC 199 tissue culture medium (Sigma,
USA) and used for HLA typing.
HLA typing
T and B lymphocytes were separated from
peripheral blood mononuclear cells by a nylon wool
column8. Eighty to hundred mg of nylon wool
(Fenwall Laboratories, USA) was evenly packed in
each column for 6 cm in a 10 cm column using a
drinking straw. The columns were rinsed with TC
199 medium containing 10% FCS. Ten million
mononuclear cells in 1 ml medium were loaded on
to nylon wool and incubated at 37°C for 40
minutes. The nylon wool non-adherent cells
(enriched T cells) were used for HLA -A and -B
typing and the nylon wool adherent population
(enriched B cells) was used for HLA -DR and -DQ
typing. HLA phenotyping was performed by a two
stage micro lymphocytoxicity assay9.
The antisera for HLA -A and -B (class-I) and
HLA -DR and -DQ (class-II) antigens were
purchased from Biotest, Germany. In addition, well
established sera of local origin8’10 and some
procured from co-operative HLA laboratories in
India were also used. At least three sera were
included for each specificity studied.
Statistical Analysis
The frequencies of HLA alleles, in patients and
controls, were determined by direct allelic count
method. A2 x 2 contingency Table was constructed
and Chi-square analysis with Yates correction was
performed for HLA antigens and haplotypes.
Relative Risk (RR) (Odd’s ratio) values were
calculated to find out the strength of the association
between HLA antigens and/or haplotypes and the
occurrence of relapse”.
RESULTS
An increased antigen frequency of HLA -Al and
-B 17 was seen in patients with bacteriological
relapse compared with those having quiescent
disease (Al P = 0.03). A trend towards an increase
in the frequency of HLA -A3, A28, B12, B40 was
also seen in the quiescent patients when compared
with relapse patients. However, the increase was
not significant. Among the HLA -DR and -DQ loci
antigens, the trend was towards an increased
frequency of DR3, DR6 and DR10 and decreased
frequency of DR5, DR8 and DR9 in patients with
relapse. The increased or decreased DR antigen
frequencies were not significant. No trend was
observed for -DQ locus antigens (Table 1).
In relapse patients, the relative risk values (RR)
were higher for Al (2.8), B17 (3.2) DR3 (2.5) and
DR6 (2.1) antigens. Further, the haplotype
frequency of Al-B17, B17-DR7, Al-DR7, Al-B8,
B8-DR3, Al-DR3 were higher in the relapse
patients than quiescent (controls) patients.
Moreover, the relative risk values were also higher
for Al-B17 (3.3), B17-DR7 (3.0) Al-DR7 (9.3) Al-
DR3 (3.3) in relapse patients. The haplotype Al-
DR7 was significantly increased in relapse patients
(P = 0.04). An increased frequency of the haplotype
B12-DR7 was seen in the quiescent patients
compared with the relapse patients. However, this
increase was not significant (P = 0.06).
DISCUSSION
In the present study, the antigen frequency of
HLA -Al,  -B17 was higher in pulmonary
tuberculosis patients who had bacteriological
relapse after completing SCC compared with
quiescent patients. Further, the haplotype frequency
of Al-B17 was also increased. Though the
haplotype Al-B17 (B57) is found mainly in
Caucasian populations 12, this haplotype is also seen
in the Indian population1 3 . The phenotype
frequency of Al and B 17 antigens and the haplotype
frequency of Al-B 17 was found to be higher in
those Indian patients who had psoriasis14. Increased
frequency of Al-DR7 and Al-DR3 haploytpes has
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Table 1 : HLA -A, -B, -DR and -DQ antigen Table 2 : Haplotype frequencies (per 10,000) in
frequencies in relapse and quiescent (controls) relapse  and quiescent  (controls)  pat ients  of
patients of pulmonary tuberculosis treated with short pulmonary tuberculosis treated with short course
course chemotherapy chemotherapy
HLA
% Phenotype frequency in
Relative Risk (RR)
Quiescent Relapse (Odd’s ratio)
(n=51) (n=51)
Haplotype frequency
Haplotypes Relative Risk (RR)
Quiescent Relapse (Odd’s ratio)
Al - B5 348 213 1.5
Al - B8 –40 299 –
Al - B12 152 67 0.5
Al - B17 176 463 3.3
Al - DR3 164 463 3.3
Al - DR5 209 31 0.7
Al - DR7 –139* 478* 9.3
A3 - B5 319 182 0.6
A3 - DR3 160 20 0.5
A3 - DR5 69 –59 0.0
A28 - B5 318 69 0.2
A28 - DR5 66 73 0.5
B5 - DR5 207 –98 0.2
B5 - DR7 336 671 1.6
B8 - DR3 –16 187 –
B12 - DR7 487** –53** 0.0
B17 - DR7 281 763 3.0
* c 2 = 4.39; P = 0.03 Significant
** c 2 = 3.36; P =0.06 Non-significant
A-locus
Al 21.6* 43.1*
A2 35.3 29.4
A3 23.5 13.7
A9 25.5 27.5
A10 15.7 15.7
A11 33.3 35.3
A19 17.6 19.6
A28 13.7 3.9
A- 15.7 11.8
B-locus
B5 39.2 41.2
B7 23.5 23.5
B8 5.9 5.9
B12 11.8 3.9
B13 9.8 13.7
B14 0.0 3.9
B15 21.6 21.6
B17 7.8** 21.6**
B21 7.8 7.8
B22 3.9 3.9
B35 29.4 21.6
B40 21.6 9.8
B- 17.6 21.6
DR-locus
DR1 11.8 7.8
DR2 49.0 52.0
DR3 9.8 21.6
DR4 29.4 21.6
DR5 21.6 13.7
DR6 5.9 11.8
DR7 29.4 37.3
DR8 7.8 2.0
DR9 11.8 5.9
DR10 9.8 15.7
DR- 13.7 9.8
DQ-locus
DQ1
DQ2
DQ3
DQ-
82.4 88.2 1.6
33.3 41.2 1.4
58.8 54.9 0.9
23.5 15.7 –
2.8
0.8
0.5
1.1
1.1
1.1
1.1
0.3
–
1.1
1.0
1.0
0.3
1.5
–
1.0
3.2
1.0
1.0
0.7
0.4
–
0.6
1.2
2.5
0.7
0.6
2.1
1.4
0.2
0.5
1.7
–
* c 2 = 4.48; P = 0.03 Significant
** c 2 = 2.8; P =0.06 Non-significant
been found in relapse pulmonary tuberculosis
patients. It has been shown that the haplotype Al-
B8-DR3 is associated with autoimmune diseases15.
In Hong Kong Chinese tuberculosis patients,
who had relapsed after 6 months or more of
inactivity, no increase or decrease in any of HLA-
antigens or haplotypes was seen16. However, the
present study shows an increase in the HLA -Al and
-B17 antigens and A1-B17, A1-DR7 and A1-DR3
haplotypes among similarly treated patients. The
present study suggests that either the antigen HLA
-A1 and/or the haplotype A1-DR7 are associated
with bacteriological relapse or the non-HLA genes
which are linked to the HLA region may be
involved in the occurrence of bacteriological
relapse in treated pulmonary tuberculosis patients.
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